Axogen (AXGN) vs CapsoVision (CV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Axogen (AXGN) has outperformed CapsoVision (CV) over the past year, gaining 107.5% versus a gain of 16.8%. Axogen is the larger company by market cap ($3.33 billion vs $327.6 million), about 10.2 times the size. Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | CV |
|---|---|---|
| Share price | $55.75 | $6.11 |
| Market cap | $3.33B | $327.56M |
| 1-day change | -1.06% | -3.17% |
| YTD return | +70.33% | -42.84% |
| 1-year return | +107.48% | +16.83% |
| 5-year return | +481.33% | — |
| Forward P/E | 79.03 | — |
| EPS (TTM) | $-0.63 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | $13.55M |
| Revenue growth (YoY) | +20.21% | +15.29% |
| Net income (latest FY) | $-15.70M | $-25.32M |
| Gross margin | 74.31% | 52.92% |
| Operating margin | -3.49% | -188.25% |
| Net margin | -6.97% | -186.77% |
| 52-week high | $59.72 | $15.37 |
| 52-week low | $26.92 | $4.50 |
| Distance from 52-week high | -6.65% | -60.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +6.31% | +55.48% |
| Average volume | 1.57M | 173.59K |
| Shares outstanding | 59.73M | 53.61M |
| Employees | 622 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 10.2 times larger than CapsoVision by market value ($3.33B vs $327.56M).
- AXGN has outperformed CV by 90.7 percentage points over the past year.
- Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
AXGN vs CV FAQ
Which is bigger, Axogen or CapsoVision?
Axogen (AXGN) is larger, with a market capitalization of $3.33B compared with $327.56M for CapsoVision (CV).
Which stock has performed better over the past year, AXGN or CV?
AXGN returned +107.48% over the past 12 months, compared with +16.83% for CV (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and CapsoVision in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.